Item 9 Labs Corp.

Equities

INLB

US46564C2035

Healthcare Facilities & Services

Market Closed - OTC Markets 09:30:02 2024-04-24 am EDT 5-day change 1st Jan Change
0.0001 USD 0.00% Intraday chart for Item 9 Labs Corp. 0.00% -94.74%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Item 9 Labs Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Douglas Bowden Resigned as Chairman of the Board of Directors of Item 9 Labs Corp, Effective July 18, 2023 CI
Douglas Bowden Resign as Interim CEO of Item 9 Labs Corp CI
Item 9 Labs Corp. Announces Resignation of Shane Evans as A Member of the Board of Directors CI
Item 9 Labs Corp. cancelled the acquisition of Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. CI
Item 9 Labs Corp. Announces Management Changes CI
Item 9 Labs Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Item 9 Labs Corp. Announces Resignation of Michael Weinberger as Member of the Board of Directors CI
Item 9 Labs Corp. Announces CEO Changes CI
Item 9 Labs Corp. Announces the Resignation of Lawrence X. Taylor as Board of Director CI
Item 9 Labs Releases Latest Limited Edition One-Gram Rosin-Infused Pre-Rolls CI
Item 9 Labs Corp. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
Item 9 Labs Corp. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Item 9 Labs Corp. Auditor Raises 'Going Concern' Doubt CI
Item 9 Labs Corp. Announces Management Promotions CI
Item 9 Labs Corp. Announces Resignation of Andrew Bowden as Director CI
Item 9 Labs Corp. Announce Chief Executive Officer Changes CI
Item 9 Labs Corp. announced that it expects to receive $25 million in funding from ClearThink Capital Partners, LLC CI
Item 9 Labs Corp. Accelerates Growth of Unity Rd. Dispensary Franchise CI
Earnings Flash (INLB) ITEM 9 LABS Reports Q3 Revenue $4.9M MT
Item 9 Labs Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022 CI
Item 9 Labs Corp. Nears Completion of Cannabis Cultivation and Lab Facility in Pahrump, Nevada CI
Item 9 Labs Chief Strategy Officer Jeffrey Rassas Resigns MT
Item 9 Labs Corp Announces Resignation of Jeffrey Rassas as the Chief Strategy Officer CI
Item 9 Labs Corp. signed a definitive agreement to acquire Sessions Cannabis from Steven Fry, Najla Guthrie, Darryl Allen, Louis Laskovski, 2628146 Ontario Ltd. and 11949896 Canada Inc. for $21 million. CI
Chart Item 9 Labs Corp.
More charts
Item 9 Labs Corp. is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The Company also offers a dispensary franchise model through the national Unity Rd. retail brand. The Company offers approximately 75 active cannabis strains and more than 150 differentiated cannabis vaporizer (vape) products, as well as premium concentrates and Orion vape technologies. The Company's Item 9 Labs brand specializes in select products and user experience across several cannabis categories. The Company operates through two segments: Cultivation and Franchising. Its product lines include Item 9 Labs Flower, Item 9 Labs Concentrates, and Orion 710.
More about the company
  1. Stock Market
  2. Equities
  3. INLB Stock
  4. News Item 9 Labs Corp.
  5. Earnings Flash (INLB) ITEM 9 LABS Reports Q3 Revenue $4.9M